Added value of systemic inflammation markers for monitoring response to neoadjuvant chemotherapy in breast cancer patients

Figure 3 Validation and comparison of the predictive model. A: Area under the receiver operating characteristic curve (AUC) to assess the performance of response after neoadjuvant chemotherapy (rNACT) risk prediction of machine learning based models; B: AUC to assess the performance of rNACT risk prediction of generalized linear model (GLM); C: Discriminative evaluation of support vector machine in predicting rNACT; D: Discriminative evaluation of GLM in predicting rNACT. SVM: Support vector machine; GLM: Generalized linear model.